HomeQuestion

Would you utilize Breast Cancer Index in patients with ER+ HER2+ breast cancer to guide whether or not to extend adjuvant endocrine therapy?

3

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Do you utilize MammaPrint testing to determine whether or not to offer neoadjuvant chemotherapy for high-risk ER+ breast cancer?

How would you manage a premenopausal female with cT2cN0 HR+/HER2-negative breast cancer who received neoadjuvant TC for high OncoType, had no pathologic response to therapy and upstaged to pT2N1 on surgery?

How would you treat an elderly patient with borderline cardiac dysfunction who has stage 3 HR+ HER2- breast cancer?

Would you use OncoType Dx to guide adjuvant therapy recommendations in the context of locally recurrent, node-negative, ER+ breast cancer previously treated with endocrine therapy alone?

Does abemaciclib have the same magnitude of benefit in patients with lobular breast cancer in adjuvant and metastatic setting compared to ductal breast cancer?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.